ARYX Stock - ARYx Therapeutics, Inc.
Unlock GoAI Insights for ARYX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 |
|---|---|---|---|---|---|
| Revenue | N/A | $19.72M | $4.16M | $4.74M | N/A |
| Gross Profit | N/A | $19.49M | $3.90M | $2.62M | N/A |
| Gross Margin | N/A | 98.8% | 93.7% | 55.3% | N/A |
| Operating Income | $-31,238,000 | $-30,417,000 | $-28,800,000 | $-28,288,000 | $-28,169,000 |
| Net Income | $-33,167,000 | $-31,218,000 | $-27,561,000 | $-27,328,000 | $-27,964,000 |
| Net Margin | N/A | -158.3% | -662.8% | -576.7% | N/A |
| EPS | $-1.21 | $-1.65 | $-2.93 | $-26.84 | $-30.73 |
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phase IIb clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat. The company's other clinical development products comprise ATI-7505, an oral prokinetic agent, which is in Phase IIb clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. It also focuses on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal disorders that are in discovery stage. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California.
Visit WebsiteEarnings History & Surprises
ARYXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2010 | Nov 15, 2010 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q3 2010 | Aug 16, 2010 | $-0.10 | $-0.11 | -10.0% | ✗ MISS |
Q2 2010 | May 13, 2010 | $-0.16 | $-0.22 | -37.5% | ✗ MISS |
Q1 2010 | Mar 29, 2010 | $-0.22 | $-0.21 | +4.5% | ✓ BEAT |
Q4 2009 | Nov 12, 2009 | — | $-0.30 | — | — |
Q3 2009 | Aug 13, 2009 | $-0.33 | $-0.34 | -3.0% | ✗ MISS |
Q2 2009 | May 14, 2009 | $-0.49 | $-0.36 | +26.5% | ✓ BEAT |
Q1 2009 | Mar 26, 2009 | $-0.57 | $-0.57 | 0.0% | = MET |
Q4 2008 | Nov 12, 2008 | $0.30 | $0.17 | -43.3% | ✗ MISS |
Q3 2008 | Aug 13, 2008 | $-0.63 | $-0.67 | -6.3% | ✗ MISS |
Q2 2008 | May 13, 2008 | $-0.34 | $-0.54 | -58.8% | ✗ MISS |
Q1 2008 | Mar 12, 2008 | $-0.75 | $-0.80 | -6.7% | ✗ MISS |
Q4 2007 | Dec 20, 2007 | $-5.98 | $-6.30 | -5.4% | ✗ MISS |
Q2 2007 | Jun 30, 2007 | — | $-5.71 | — | — |
Q1 2007 | Mar 31, 2007 | — | $-5.71 | — | — |
Q4 2006 | Dec 31, 2006 | — | $-4.57 | — | — |
Q3 2006 | Sep 30, 2006 | — | $-4.57 | — | — |
Q2 2006 | Jun 30, 2006 | — | $-8.95 | — | — |
Q1 2006 | Mar 31, 2006 | — | $-8.95 | — | — |
Q4 2005 | Dec 31, 2005 | — | $-7.68 | — | — |
Latest News
Frequently Asked Questions about ARYX
What is ARYX's current stock price?
What is the analyst price target for ARYX?
What sector is ARYx Therapeutics, Inc. in?
What is ARYX's market cap?
Does ARYX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ARYX for comparison